Zymeworks Inc.

Zymeworks Inc.

ZYMENYSE / NASDAQHealthcareSmall cap

$26.14-$0.72 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$1.8B
P/E
-22.8x
EV / EBITDA
-22.4x
Revenue
$106.0M
Net margin
-76.6%
ROCE
-30.4%

+9.7% over the last year

Zymeworks Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-2.9%
3M
-1.6%
6M
+5.2%
1Y
+9.7%
5Y
+32.0%

52-week range

Day change -$0.72 (-2.7%) from $26.86 to $26.14 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ZYME, bought on each weekday since 2021.

News & filings

What Zymeworks filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 81.1 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 38.9% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.

Read moreShow less

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Sector
Healthcare
Shares outstanding
75.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.8B
P/E
-22.8x
P/B
6.9x
EV / EBITDA
-22.4x
EV / Sales
17.2x
P/S
17.4x
52-week high
$31.46
52-week low
$21.81

Profitability

Operating margin
-87.3%
Net margin
-76.6%
EBITDA margin
-76.8%
ROE
-30.2%
ROCE
-30.4%
ROIC
-29.8%
ROA
-23.4%
Asset turnover
0.31

Growth

Revenue
$106.0M
Revenue growth, 1Y
38.9%
Revenue CAGR, 3Y
-36.4%
Net profit growth, 1Y
-33.9%
Free cash flow
-$35.4M

Solvency

Current ratio
5.88
Debt / Equity
0.07
Debt / Assets
0.05
CFO / Net profit
0.41
Cash / Market cap
2.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$106.0M
Gross profit$106.0M
Operating expenses$198.5M
Research and development$137.0M
Selling, general and administrative$61.5M
Operating income-$92.5M
Interest and other$12.8M
Pretax income-$79.8M
Tax and other$1.4M
Net income-$81.1M

Revenue and net profit

Revenue grew 38.9% in FY2025; net profit is the dashed line.

Zymeworks Inc. revenue and net profit by fiscal year
Zymeworks Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$412.5M$124.3M
FY2023$76.0M-$118.7M
FY2024$76.3M-$122.7M
FY2025$106.0M-$81.1M

Cash flows

FY2025: -$33.0M from operations, -$35.4M free after investment (dashed).

Zymeworks Inc. operating and free cash flow by fiscal year
Zymeworks Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$144.1M$131.0M
FY2023-$118.3M-$122.4M
FY2024-$110.1M-$113.1M
FY2025-$33.0M-$35.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$106.0M+38.9%1Y
EBITDA
-$81.4M
Net profit
-$81.1M
Cash from operations
-$33.0M
Free cash flow
-$35.4M
Revenue CAGR, 3Y
-36.4%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$106.0M-$81.4M-$81.1M-$35.4M-30.2%+38.9%-33.9%

Monthly returns

Month-by-month returns of ZYME across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$346.5M
Liabilities$78.0M
Equity$268.5M
Paid-in capital$114.6M
Retained earnings-$953.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ZYME highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Zymeworks Inc. (this company)17.2x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Zymeworks Inc.ZYMEthis company$1.8B-22.8x6.9x-30.2%-22.4x
Astrana Health, Inc.ASTH$1.9B83.5x2.4x2.9%18.7x
Stoke Therapeutics, Inc.STOK$1.9B-272.5x5.3x-2.0%-95.4x
Pulse Biosciences, Inc.PLSE$1.9B-25.6x23.1x-90.2%-23.6x
Maravai LifeSciences Holdings, Inc.MRVI$1.8B-14.1x8.7x-61.6%-13.5x
Pediatrix Medical Group, Inc.MD$1.8B11.1x2.1x19.1%7.6x
Viridian Therapeutics, Inc.VRDN$1.8B-5.3x3.1x-58.1%-4.9x
Vericel CorporationVCEL$1.8B110.3x5.1x4.7%60.3x
ANI Pharmaceuticals, Inc.ANIP$1.8B23.0x3.3x14.5%10.3x
Peer median—2.9x4.2x0.5%1.3x

Year-to-date ROI

ZYME since 1 January, against earlier years.

Historical volatility

ZYME's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Zymeworks Inc. operating margin by fiscal year
Zymeworks Inc. operating margin by fiscal year
DateOperating margin
FY202231.6%
FY2023-181.6%
FY2024-157.0%
FY2025-87.3%
LineFY2025
Operating expensesOperating Expense$198.5M
Research and developmentResearch And Development$137.0M
Total expensesTotal Expenses$198.5M
Pretax incomePretax Income-$79.8M

Learn while you research

Academy chapters picked for Zymeworks Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing39% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →